What Are the Benefits of a Single-Tablet Therapy for HIV?

How the Pill Count Affects Your Risk of Hospitalization

The treatment of HIV has traditionally been complicated as it requires multiple antiretroviral drugs to fully suppress the virus. Therapies typically involved three or more drugs from at least two different classes, each with distinct mechanisms of action and drug half-lives (the speed by which the drug is eliminated from the body).

In the past, this posed serious problems as older drugs like Crixivan (indinavir) required three pills every eight hours, while others like Zerit (stavudine) and Epivir (lamivudine) required dosing every 12 hours. For a therapy like this, you would need to take a dose four to five times a day, every day to achieve viral suppression.

Man holding HIV medication cocktail, close-up
Bruce Forster / Photographer's Choice / Getty Images

Today, these concerns have largely been overcome as improved pharmacokinetics have extended the half-life of many of the drugs, allowing them to be taken once daily without the risk of toxicity. There are even therapies today that require only two rather than the traditional three drugs to achieve the same durable suppressive effect.

On top of this, more and more antiretrovirals are being co-formulated into combination tablets that have reduced the pill burden to as few as one pill daily. Clearly, by taking fewer pills, managing HIV becomes far easier and less impactful on your life and well-being.

But the benefits extend well beyond the ease of use.

Fixed-Dose Combination Tablets

Today, there are over 25 different antiretroviral drugs approved by the Food and Drug Administration (FDA). Many of these individual agents have been co-formulated into fixed-dose combination (FDC) tablets that are either used on their own or with other antiretroviral drugs.

Of the 22 FDC tablets approved by the FDA, 13 can be used on their own as a complete, once-daily therapy:

Pill Burden and Adherence

The first major benefit of a once-daily, single-pill regimen is the ease of use. You simply take one pill in the morning (or sometimes before bedtime) and that's it for the day.

This greatly improves treatment adherence (the practice of taking your drugs as prescribed on a regular basis). This, in turn, reduces the risk of drug resistance by ensuring that the concentration of drugs in your body remains at a constant therapeutic level.

By maintaining a consistent drug concentration, the virus is suppressed to undetectable levels. This is best achieved by taking your drugs every day as prescribed. While it normal to miss the occasional dose, maintaining adherence is the best way to ensure durable viral suppression.

This is not always as easy as it sounds. According to statistics from the Department of Health and Human Services, roughly one in three people on antiretroviral therapy in the United States are unable to achieve an undetectable viral load. Poor adherence is a major cause of this.

By reducing the daily pill burden to one tablet daily, studies have shown the rate of adherence can be significantly increased along with the rates of viral suppression.

According to a 2018 study from British Columbia Center for Excellence in HIV/AIDS, adding just one pill to the daily antiretroviral regimen reduces the odds of optimal adherence by 13%. By contrast, having a once-daily, single-pill option increases the odds of optimal adherence by 36% compared to multi-pill regimens.

Pill Burden and Hospitalization

Beyond the issue of drug resistance, taking one pill daily appears to improve the overall health of people living with HIV.

A 2016 study from the University of South Carolina examined the relationship between antiretroviral pill burden and the rate of hospitalizations among 2,174 Medicaid recipients in South Carolina from 2006 to 2013. In total, 580 people were on a single-pill regimen, while 1,594 were prescribed a multi-pill regimen involving two or more drugs.

According to the researchers, people on the single-pill regimen had higher rates of complete viral suppression (64.5% vs 49.5%) and experienced 29% fewer hospitalizations compared to those on a multi-pill regimen.

A similar study from the University of North Carolina, Chapel Hill in 2013 concluded that a high pill burden is linked to increased rates of non-HIV-associated illnesses in people with HIV. (Today, non-HIV-associated diseases like cancer and heart disease are the leading causes of death in people living with HIV in the developed world.)

According to research, having a high daily pill burden increases the risk of hypertension and high cholesterol by 42% and 32%, respectively. Both are linked to an increased risk of coronary artery disease, a condition that is 61% more common in people with HIV than in the general population.

Limitations of Use

As attractive as the daily one-pill option may seem, not everyone is a candidate. There are several factors that can limit their use, whether you are being newly treated for HIV or changing treatment. These include:

  • Drug resistance: Prior to starting a new therapy, you will undergo genetic resistance testing to see which drugs you are resistant to. Even if you are newly infected, it is possible to acquire a resistant mutation that limits the number of drugs you are sensitive to.
  • Drug contraindications: Certain pre-existing health conditions may disqualify certain drugs, including the use of tenofovir in people with severe kidney disease or the use of efavirenz in people with serious psychiatric conditions.
  • Drug hypersensitivity: With abacavir, genetic testing is performed to ensure that you don't have the HLA-B*5701 mutation which predicts the likelihood of a serious and potentially life-threatening drug hypersensitivity reaction.
  • Drug tolerability: Some people will tolerate certain drugs better than others. If side effects are severe or intolerable, the drug may need to be discontinued.

Despite these limitations, the increasing number of FDC drugs means that newly treated people are more likely than not to find a once-daily option that works.

Another limiting factor is cost. Many all-in-one antiretrovirals are placed on a high tier on insurance drug formularies, requiring higher out-of-pocket copay or coinsurance costs. Although manufacturer assistance programs are available, the assistance may still not be enough to make the drug affordable to the underinsured or uninsured.

Of the 13 all-in-one FDC drugs approved by the FDA, only Atripla is available in a generic form. The next drug whose patent is set to expire is Triumeq in 2027.

Advances in Treatment

In January 2021, the very concept of antiretroviral treatment was turned on its ear with the approval of Cabenuva (cabotegravir and rilpivirine). Delivered by injection monthly or every two months—with one shot of the drug rilpivirine and one shot of a novel integrase inhibitor cabotegravir—Cabenuva has been shown to provide the same level of viral control as traditional once-daily antiretroviral therapy.

The cost of treatment may be an impediment given the monthly average wholesale price of Cabenuva is $4,754. Moreover, it is unclear if health insurers will add it to their drug formularies and under what conditions.

It is also unclear if going into your healthcare provider's office monthly or every two months for a shot is necessarily more convenient than taking your pills every day at home.

Even so, Cabenuva can better ensure adherence in people unable to do so on their own, while providing healthcare providers a means to track adherence and intervene when necessary.

A Word From Verywell

As attractive as a once-daily, single-pill option sounds, don't change treatment simply for the sake of changing. If you are able to sustain an undetectable viral load on your current therapy, it may be better to stay the course.

If, on the other hand, you have been struggling with adherence (such as if you have an irregular work schedule), ask your healthcare provider if a single-pill option is right for you. Anything that makes it easier for you to take your drugs is likely to improve their effectiveness and durability.

14 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. U.S. Department of Health and Human Services. FDA-approved HIV medications.

  2. Afiqah N, Salle M, Richardson L, et al. A longitudinal analysis of daily pill burden and the likelihood of optimal adherence to antiretroviral therapy among people living with HIV who use drugs. J Addict Med. Jul/Aug 2018;12(4):308-14. doi:10.1097/ADM.0000000000000403

  3. HIV.gov. What is the HIV care continuum?

  4. Sutton SS, Magagnoli J, Hardin JW. Impact of pill burden on adherence, risk of hospitalization, and viral suppression in patients with HIV infection and AIDS receiving antiretroviral therapy. Pharmacotherapy. 2016 Apr;36(4):385-401. doi:10.1002/phar.1728

  5. Zhou S, Martin K, Corbett A, et al. Total daily pill burden in HIV-infected patients in the southern United States. AIDS Patient Care STDS. 2014 Jun 1;28(6):311-7. doi:10.1089/apc.2014.0010

  6. Nishijima T, Inaba Y, Kawasaki Y, et al. Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan. AIDS. 2020 May;34(6):913-21. doi:10.1097/QAD.0000000000002498

  7. Triant VA. Epidemiology of coronary heart disease in HIV patients. Rev Cardiovasc Med. 2014;15(01):S1-8.

  8. Panichsillapakit T, Smith DM Wertheim JO, Richman DD, Little SJ, Mehta SR. Prevalence of transmitted HIV drug resistance among recently infected persons in San Diego, California 1996-2013. J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):228-36. doi:10.1097/QAI.0000000000000831

  9. Gilani B, Budh DP. HLA B 5701 testing. In: StatPearls [Internet].

  10. Bristol-Myers Squibb. Package insert - Atripla.

  11. U.S. Securities and Exchange Commission. Form 10-K Annual Report: Gilead Sciences.

  12. Food and Drug Administration. Cabenuva label.

  13. U.S. Food and Drug Administration. FDA approves first extended-release, injectable drug regimen for adults living with HIV.

  14. Test Positive Aware Network. Cabenuva.

By Elizabeth Boskey, PhD
Elizabeth Boskey, PhD, MPH, CHES, is a social worker, adjunct lecturer, and expert writer in the field of sexually transmitted diseases.